Sugi Predict

Sugi Predict / Compounds / SCHEMBL954348

SCHEMBL954348

SCHEMBL954348

N#CCC(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.62
▸ MAPK1 P28482 1/20 0.62
▸ HIF1A Q16665 1/20 0.62
▸ ERCC5 P28715 1/20 0.56
▸ FEN1 P39748 1/20 0.56
▸ TSHR P16473 1/20 0.53
▸ CASP1 P29466 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ MAPT P10636 4/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ GABRA1 P14867 6/20 0.49
▸ GABRG2 P18507 6/20 0.49
▸ GABRB3 P28472 6/20 0.49
▸ GABRB2 P47870 4/20 0.49
▸ GABRB1 P18505 2/20 0.49
▸ KCNH2 Q12809 1/20 0.48
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29487646 1.00 ALDH1A1 (0.62) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL11331688 0.86 ERCC5 (0.56) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL31515465 0.83 MAPT (0.49) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL31688020 0.83 CTSL (0.47) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL1855966 0.83 CTSL (0.47) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL4151911 0.83 KCNH2 (0.46) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL2520383 0.83 MAPT (0.49) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL12694520 0.81 MAPT (0.50) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL29403310 0.79 MAPT (0.59) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL11350806 0.79 MAPT (0.59) ALDH1A1MAPK1HIF1AERCC5FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143184-B1 COMPOUNDS USEFUL FOR INHIBITING RET KINASE LILLY CO ELI (US) 2025-04-23 — — EP disclosed
US-11964968-B2 Compounds useful for inhibiting RET kinase ELI LILLY AND COMPANY (US) 2024-04-23 — — US disclosed
US-20230312544-A1 COMPOUNDS USEFUL FOR INHIBITING RET KINASE LOXO ONCOLOGY, INC. 2023-10-05 — — US disclosed
US-11613533-B2 Compounds useful for inhibiting RET kinase ELI LILLY AND COMPANY (US) 2023-03-28 — — US disclosed
EP-4143184-A1 COMPOUNDS USEFUL FOR INHIBITING RET KINASE Eli Lilly and Company (US) 2023-03-08 — — EP disclosed
CN-115667253-A Compounds useful for inhibition of RET kinase 伊莱利利公司 2023-01-31 — — CN disclosed
CN-109280028-B Quinoline compound and application thereof in DPP-4 enzyme inhibitor 上海医药工业研究院 2022-03-25 — — CN disclosed
US-11192893-B2 Pyrazoloquinazolinone antitumor agents THE ROCKEFELLER UNIVERSITY (US) 2021-12-07 — — US disclosed
US-11192893-B2 Pyrazoloquinazolinone antitumor agents THE ROCKEFELLER UNIVERSITY (US) 2021-12-07 — — US disclosed
US-20210363140-A1 COMPOUNDS USEFUL FOR INHIBITING RET KINASE LOXO ONCOLOGY, INC. 2021-11-25 — — US disclosed
US-4990646-A Preparation of halogenated quinolonecarboxylic acids BAYER AKTIENGESELLSCHAFT (DE) 1991-02-05 — — US disclosed
US-4914228-A Preparation of halogenated quinolonecarboxylic acids BAYER AKTIENGESELLSCHAFT (DE) 1990-04-03 — — US disclosed
US-4782156-A Nitriles of halogenated quinolonecarboxylic acids BAYER AKTIENGESELLSCHAFT (DE) 1988-11-01 — — US disclosed
US-4680401-A Preparation of halogenated quinolonecarboxylic acids BAYER AKTIENGESELLSCHAFT (DE) 1987-07-14 — — US disclosed
EP-0168737-A2 Process for the preparation of halogenated quinolinoncarboxylic acids BAYER AG (DE) 1986-01-22 — — EP disclosed
US-4259256-A ANTIINFLAMMATORY AMERICAN CYANAMID COMPANY (US) 1981-03-31 — — US disclosed
EP-0016277-A1 2-Carbonyl-3-hydroxy-alkenonitriles, their use as anti-arthritic agents and processes for their preparation AMERICAN CYANAMID COMPANY (US) 1980-10-01 — — EP disclosed
WO-1980000964-A1 ANTI-INFLAMMATORY AGENTS INCLUDING 2-CARBONYL-3-HYDROXY-2-ALKENONITRILES AMERICAN CYANAMID CO (US) 1980-05-15 — — WO disclosed
US-4181677-A ANTIINFLAMMATORY AGENTS AMERICAN CYANAMID COMPANY (US) 1980-01-01 — — US disclosed
US-4173650-A ANTIARTHRITIC AGENTS AMERICAN CYANAMID COMPANY (US) 1979-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11613533-B2 Compounds useful for inhibiting RET kinase RET, GFRA3, GFRA1 ALDH1A1 2702/4885MAPK1 241/4885HIF1A 1935/4885
US-20210363140-A1 COMPOUNDS USEFUL FOR INHIBITING RET KINASE RET, GFRA3, GFRA1 ALDH1A1 2702/4885MAPK1 241/4885HIF1A 1935/4885
US-20230312544-A1 COMPOUNDS USEFUL FOR INHIBITING RET KINASE RET, GFRA3, GFRA1 ALDH1A1 2702/4885MAPK1 241/4885HIF1A 1935/4885
US-11964968-B2 Compounds useful for inhibiting RET kinase RET, GFRA3, GFRA1 ALDH1A1 2702/4885MAPK1 241/4885HIF1A 1935/4885
US-11192893-B2 Pyrazoloquinazolinone antitumor agents H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 ALDH1A1 317/4885MAPK1 4003/4885HIF1A 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.